Literature DB >> 3829580

Plasma biguanide levels are correlated with metabolic effects in diabetic patients.

P Marchetti, L Benzi, P Cecchetti, R Giannarelli, C Boni, D Ciociaro, A M Ciccarone, G Di Cianni, A Zappella, R Navalesi.   

Abstract

Metabolic abnormalities occur in biguanide-treated diabetic patients. We investigated the relationship between plasma metformin and phenformin concentrations and metabolic effects. Drug levels were measured in 37 type II diabetic patients by HPLC. The method was sensitive, specific, and linear over a wide range of drug concentrations. Metformin and phenformin values ranged from 236 to 718 ng/ml and from 28 to 114 ng/ml, respectively. The plasma metformin level was correlated with triglycerides (r = -0.55; P less than 0.05) but not with drug dosage, plasma glucose, HbA1, creatinine, creatinine clearance, lactate, pyruvate, lipid, and clinical parameters. Plasma phenformin concentrations correlated with lactate (r = 0.49; P less than 0.05) and HbA1 (r = 0.50; P less than 0.05) but not with drug dosage, parameters of diabetes control, creatinine, creatinine clearance, pyruvate, and clinical parameters. The clinical usefulness of this HPLC method, the evidence that the increase of lactate is related to the circulating phenformin levels, and the demonstration that the metformin effect on triglyceride metabolism is correlated to plasma drug levels are the positive findings of this work.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829580     DOI: 10.1038/clpt.1987.55

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Authors:  Silvio E Inzucchi; Kasia J Lipska; Helen Mayo; Clifford J Bailey; Darren K McGuire
Journal:  JAMA       Date:  2014 Dec 24-31       Impact factor: 56.272

2.  Effect of plasma metformin concentrations on serum lipid levels in type II diabetic patients.

Authors:  P Marchetti; L Benzi; M Cerri; P Cecchetti; R Giannarelli; M Giannecchini; G Di Cianni; R Cristofani; R Miccoli; A Bertolotto
Journal:  Acta Diabetol Lat       Date:  1988 Jan-Mar

Review 3.  Clinical pharmacokinetics of metformin.

Authors:  A J Scheen
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

Review 4.  Lactate Levels with Chronic Metformin Use: A Narrative Review.

Authors:  Weiyi Huang; Ronald L Castelino; Gregory M Peterson
Journal:  Clin Drug Investig       Date:  2017-11       Impact factor: 2.859

5.  From caffeine to fish waste: amine compounds present in food and drugs and their interactions with primary amine oxidase.

Authors:  Aldo Olivieri; Daniel Rico; Zhied Khiari; Gary Henehan; Jeff O'Sullivan; Keith Tipton
Journal:  J Neural Transm (Vienna)       Date:  2011-03-04       Impact factor: 3.575

Review 6.  Therapeutic Concentrations of Metformin: A Systematic Review.

Authors:  Farshad Kajbaf; Marc E De Broe; Jean-Daniel Lalau
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

Review 7.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 8.  Use of metformin in the setting of mild-to-moderate renal insufficiency.

Authors:  Kasia J Lipska; Clifford J Bailey; Silvio E Inzucchi
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

9.  Results from 11C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly.

Authors:  Ane B Iversen; Michael R Horsman; Steen Jakobsen; Jonas B Jensen; Christian Garm; Niels Jessen; Peter Breining; Jørgen Frøkiær; Morten Busk
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

10.  Cardiac Arrhythmias and Antiarrhythmic Drugs: An Autophagic Perspective.

Authors:  Joanne J A van Bavel; Marc A Vos; Marcel A G van der Heyden
Journal:  Front Physiol       Date:  2018-02-23       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.